

Je-Jung Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4614830/publications.pdf>

Version: 2024-02-01

229
papers

5,508
citations

136950

32
h-index

102487

66
g-index

231
all docs

231
docs citations

231
times ranked

6761
citing authors

#	ARTICLE	IF	CITATIONS
1	Expansion of cytotoxic natural killer cells in multiple myeloma patients using K562 cells expressing OX40 ligand and membrane-bound IL-18 and IL-21. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 613-625.	4.2	14
2	Clinical trial participation improves survival outcomes by increasing availability of new therapeutic agents in multiple myeloma. <i>British Journal of Haematology</i> , 2022, 196, 1117-1120.	2.5	2
3	Diagnostic Accuracy and Prognostic Relevance of Immunoglobulin Heavy Chain Rearrangement and 18F-FDG-PET/CT Compared With Unilateral Bone Marrow Trephination for Detecting Bone Marrow Involvement in Patients With Diffuse Large B-Cell Lymphoma. <i>Journal of Korean Medical Science</i> , 2022, 37, e2.	2.5	2
4	Real-world evidence of levofloxacin prophylaxis in elderly patients with newly diagnosed multiple myeloma who received bortezomib, melphalan, and prednisone regimen. <i>Blood Research</i> , 2022, 57, 51-58.	1.3	3
5	Novel IL-15 dendritic cells have a potent immunomodulatory effect in immunotherapy of multiple myeloma. <i>Translational Oncology</i> , 2022, 20, 101413.	3.7	4
6	Relapse with plasmacytoma after upfront autologous stem cell transplantation in multiple myeloma. <i>Annals of Hematology</i> , 2022, 101, 1217-1226.	1.8	2
7	Update on primary plasma cell leukemia. <i>Blood Research</i> , 2022, 57, S62-S66.	1.3	7
8	Characteristics and clinical outcome of high-risk multiple myeloma patients in Korea (KMM 1805). <i>International Journal of Hematology</i> , 2022, , 1.	1.6	0
9	Natural killer cells have a synergistic anti-tumor effect in combination with chemoradiotherapy against head and neck cancer. <i>Cytotherapy</i> , 2022, 24, 905-915.	0.7	11
10	Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 31-45.	4.2	20
11	Adrenal insufficiency in hospitalized patients with multiple myeloma. <i>Leukemia and Lymphoma</i> , 2021, 62, 501-503.	1.3	2
12	Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing. <i>Bone Marrow Transplantation</i> , 2021, 56, 1159-1170.	2.4	10
13	Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone. <i>International Journal of Hematology</i> , 2021, 113, 81-91.	1.6	3
14	Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial. <i>Annals of Hematology</i> , 2021, 100, 2051-2059.	1.8	6
15	Branched Muropeptide-combined Adjuvants Potentially Improve the Antitumor Effects on Glioblastoma. <i>Journal of Immunotherapy</i> , 2021, 44, 151-161.	2.4	2
16	Pilot Study: Quantitative Photoacoustic Evaluation of Peripheral Vascular Dynamics Induced by Carfilzomib In Vivo. <i>Sensors</i> , 2021, 21, 836.	3.8	8
17	A combination of immunoadjuvant nanocomplexes and dendritic cell vaccines in the presence of immune checkpoint blockade for effective cancer immunotherapy. <i>Cellular and Molecular Immunology</i> , 2021, 18, 1599-1601.	10.5	6
18	Expanded natural killer cells augment the antimyeloma effect of daratumumab, bortezomib, and dexamethasone in a mouse model. <i>Cellular and Molecular Immunology</i> , 2021, 18, 1652-1661.	10.5	20

#	ARTICLE	IF	CITATIONS
19	Favorable Long-Term Outcomes with Autologous Stem Cell Transplantation for High-Risk Multiple Myeloma Patients with a Positive Result On 18F-FDG PET/CT at Baseline. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.4	1
20	Limited benefits of thalidomide and dexamethasone maintenance after autologous stem cell transplantation in newly diagnosed multiple myeloma patients: a prospective phase II multi-center study in Korea. <i>Current Problems in Cancer</i> , 2021, 46, 100786.	2.0	0
21	Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial. <i>International Journal of Hematology</i> , 2021, 114, 653-663.	1.6	3
22	Prognostic impact of 18F-FDG PET/CT in patients with multiple myeloma presenting with renal impairment. <i>International Journal of Hematology</i> , 2021, 113, 668-674.	1.6	0
23	Daratumumab monotherapy for relapsed/refractory multiple myeloma, focussed on clinical trialâ€œunfit patients and subsequent therapy. <i>British Journal of Haematology</i> , 2021, 193, 101-112.	2.5	12
24	Variant Allele Frequency Status in Elderly Patients with Acute Myeloid Leukemia Can be Early Predictors of Responsiveness to Decitabine Treatment. <i>Blood</i> , 2021, 138, 3450-3450.	1.4	0
25	Development of a new clinical index to easily assess frailty of elderly patients with multiple myeloma in Asian population. <i>Scientific Reports</i> , 2021, 11, 22907.	3.3	3
26	Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and 18F-FDG PET/CT. <i>Blood Cancer Journal</i> , 2021, 11, 190.	6.2	10
27	Prevalence and Risk Factors for Adrenal Insufficiency in Patients with Multiple Myeloma Receiving Long-Term Chemotherapy including Corticosteroids: A Retrospective Cohort Study. <i>BioMed Research International</i> , 2021, 2021, 1-8.	1.9	3
28	Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e97-e104.	0.4	2
29	Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWPâ€œ164) Tj ETQq1 1 Q.784314 ogBT /Over		
30	The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study). <i>Annals of Hematology</i> , 2020, 99, 309-319.	1.8	5
31	Prognostic significance of FDG-PET/CT in determining upfront autologous stem cell transplantation for the treatment of peripheral T cell lymphomas. <i>Annals of Hematology</i> , 2020, 99, 83-91.	1.8	5
32	Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma. <i>BMC Cancer</i> , 2020, 20, 803.	2.6	18
33	Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk. <i>Journal of Hematology and Oncology</i> , 2020, 13, 115.	17.0	32
34	RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia. <i>Scientific Reports</i> , 2020, 10, 20119.	3.3	6
35	Feasibility of dendritic cell-based vaccine against glioblastoma by using cytoplasmic transduction peptide (CTP)-fused protein antigens combined with anti-PD1. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 2840-2848.	3.3	4
36	Autologous stem cell transplantation in elderly patients with multiple myeloma in Korea: the KMM1807 study. <i>International Journal of Hematology</i> , 2020, 112, 84-95.	1.6	5

#	ARTICLE	IF	CITATIONS
37	Peptide Vaccine Combined Adjuvants Modulate Anti-tumor Effects of Radiation in Glioblastoma Mouse Model. <i>Frontiers in Immunology</i> , 2020, 11, 1165.	4.8	14
38	Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis. <i>Leukemia and Lymphoma</i> , 2020, 61, 2714-2721.	1.3	5
39	Quantitative Assessment of Interim PET/CT Could Have More Prognostic Relevance than Visual Assessment for Predicting Clinical Outcome of Extranodal Diffuse Large B Cell Lymphoma. <i>In Vivo</i> , 2020, 34, 2127-2134.	1.3	3
40	Frontline therapy for newly diagnosed patients with multiple myeloma. <i>Blood Research</i> , 2020, 55, S37-S42.	1.3	12
41	Clinical Course of High-Risk Multiple Myeloma Patients in Korea: A Multicenter Retrospective Study. <i>Blood</i> , 2020, 136, 14-14.	1.4	0
42	The Asia-Pacific Myeloma and Related Diseases Registry: Preliminary Results of Real-World Treatment Patterns and Clinical Outcomes. <i>Blood</i> , 2020, 136, 30-31.	1.4	0
43	Carfilzomib Thalidomide and Dexamethasone Is Safe and Effective in the Treatment of Relapsed/Refractory Multiple Myeloma: An Open Label Phase II Australasian Leukaemia and Lymphoma Group (ALLG) MM 018/ Asian Myeloma Network (AMN) 002 Study. <i>Blood</i> , 2020, 136, 39-40.	1.4	0
44	Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 123.	7.4	143
45	Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019, 54, 2051-2059.	2.4	2
46	Canine non-B, non-T NK lymphocytes have a potential antibody-dependent cellular cytotoxicity function against antibody-coated tumor cells. <i>BMC Veterinary Research</i> , 2019, 15, 339.	1.9	7
47	Optimal chemo-mobilization for the collection of peripheral blood stem cells in patients with multiple myeloma. <i>BMC Cancer</i> , 2019, 19, 59.	2.6	11
48	Remission clone in acute myeloid leukemia shows growth advantage after chemotherapy but is distinct from leukemic clone. <i>Experimental Hematology</i> , 2019, 75, 26-30.	0.4	1
49	A novel TLR4 binding protein, 40S ribosomal protein S3, has potential utility as an adjuvant in a dendritic cell-based vaccine. , 2019, 7, 60.		33
50	A Phase I/II, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Lower Doses of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: The KMM103 Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1312-1319.	2.0	8
51	Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study. <i>Leukemia and Lymphoma</i> , 2019, 60, 2122-2133.	1.3	12
52	Efficacy and Safety of Melphalan, Cyclophosphamide and Dexamethasone (MCD) as a Salvage Treatment for Patients with Relapsed/Refractory Multiple Myeloma. <i>Chonnam Medical Journal</i> , 2019, 55, 25.	0.9	3
53	Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e163.	0.4	2
54	18F-FDG PET/CT is useful for determining survival outcomes of patients with multiple myeloma classified as stage II and III with the Revised International Staging System. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 107-115.	6.4	34

#	ARTICLE	IF	CITATIONS
55	Brief report: Clinical experiences after emergency use of daratumumab monotherapy for relapsed or refractory multiple myeloma in real practice. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 92-95.	1.3	10
56	Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone. <i>International Journal of Hematology</i> , 2019, 109, 79-90.	1.6	9
57	A Combination Therapy with Dendritic Cells, Pomalidomide and Programmed Death-Ligand 1 Blockade Exerts a Potent Antitumor Immunity in a Murine Model of Multiple Myeloma. <i>Blood</i> , 2019, 134, 1819-1819.	1.4	2
58	Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk: Updated subgroup analysis of CASTOR.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8040-8040.	1.6	1
59	Cellular immunotherapy in multiple myeloma. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 954-965.	1.7	9
60	Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150). <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 923-929.	2.0	10
61	A prognostic scoring system for patients with multiple myeloma classified as stage II with the Revised International Staging System. <i>British Journal of Haematology</i> , 2018, 181, 707-710.	2.5	12
62	Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. <i>Blood</i> , 2018, 131, 301-310.	1.4	216
63	The Derived Neutrophil-to-Lymphocyte Ratio Is an Independent Prognostic Factor in Transplantation Ineligible Patients with Multiple Myeloma. <i>Acta Haematologica</i> , 2018, 140, 146-156.	1.4	13
64	Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. <i>Haematologica</i> , 2018, 103, 2079-2087.	3.5	225
65	Impact of Consolidation Cycles Before Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e529-e535.	0.4	0
66	Comparison of Phenotypic and Functional Characteristics Between Canine Non-B, Non-T Natural Killer Lymphocytes and CD3+CD5dimCD21 ^{hi} Cytotoxic Large Granular Lymphocytes. <i>Frontiers in Immunology</i> , 2018, 9, 841.	4.8	30
67	Lenalidomide and Programmed Death-1 Blockade Synergistically Enhances the Effects of Dendritic Cell Vaccination in a Model of Murine Myeloma. <i>Frontiers in Immunology</i> , 2018, 9, 1370.	4.8	49
68	Clinical response and pharmacokinetics of bendamustine as a component of salvage R-B(O)AD therapy for the treatment of primary central nervous system lymphoma (PCNSL). <i>BMC Cancer</i> , 2018, 18, 729.	2.6	6
69	A novel function of API5 (apoptosis inhibitor 5), TLR4-dependent activation of antigen presenting cells. <i>Oncolmmunology</i> , 2018, 7, e1472187.	4.6	12
70	Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model. <i>Frontiers in Immunology</i> , 2018, 9, 1798.	4.8	32
71	Prostate Cancer Cell-Specific Cytotoxicity of Sub-Micron Potassium Niobate Powder. <i>Journal of Nanoscience and Nanotechnology</i> , 2018, 18, 3141-3147.	0.9	3
72	Assessment of a new genomic classification system in acute myeloid leukemia with a normal karyotype. <i>Oncotarget</i> , 2018, 9, 4961-4968.	1.8	19

#	ARTICLE	IF	CITATIONS
73	Can bortezomib combined chemotherapy be helpful for even elderly unfit patients with newly diagnosed multiple myeloma.. Journal of Clinical Oncology, 2018, 36, e20020-e20020.	1.6	0
74	18f-FDG PET/CT and the Revised International Staging System Are More Discriminating of Survival Outcomes in Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 4483-4483.	1.4	0
75	Enhancement of Antitumor Immunity Using Dendritic Cells Combined with Lenalidomide and Programmed Death Ligand-1 Blockade in Multiple Myeloma Mouse Model. Blood, 2018, 132, 3194-3194.	1.4	0
76	In silico analysis of the deleterious nsSNPs (missense) in the homeobox domain of human HOXB13 gene responsible for hereditary prostate cancer. Chemical Biology and Drug Design, 2017, 90, 188-199.	3.2	9
77	Immunotherapy for the treatment of multiple myeloma. Critical Reviews in Oncology/Hematology, 2017, 111, 87-93.	4.4	33
78	Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial. British Journal of Haematology, 2017, 176, 743-749.	2.5	14
79	Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study. Cancer Medicine, 2017, 6, 100-108.	2.8	5
80	Computational Modeling of complete HOXB13 protein for predicting the functional effect of SNPs and the associated role in hereditary prostate cancer. Scientific Reports, 2017, 7, 43830.	3.3	36
81	Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy. American Journal of Hematology, 2017, 92, 1280-1286.	4.1	34
82	Lenalidomide enhances the function of dendritic cells generated from patients with multiple myeloma. Experimental Hematology, 2017, 46, 48-55.	0.4	53
83	Generation of potent cytotoxic T lymphocytes against in male patients with non-muscle invasive bladder cancer by dendritic cells loaded with dying T24 bladder cancer cells. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2017, 43, 615-627.	1.5	7
84	STAT3 expression is associated with poor survival in non-elderly adult patients with newly diagnosed multiple myeloma. Blood Research, 2017, 52, 293.	1.3	23
85	Daratumumab, bortezomib and dexamethasone (DvD) vs bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and safety update (CASTOR).. Journal of Clinical Oncology, 2017, 35, 8036-8036.	1.6	4
86	5-Hydroxymethylcytosine correlates with epigenetic regulatory mutations, but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemia. Oncotarget, 2017, 8, 8305-8314.	1.8	6
87	A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma. Oncotarget, 2017, 8, 41538-41548.	1.8	39
88	Combination therapy with dendritic cells and lenalidomide is an effective approach to enhance antitumor immunity in a mouse colon cancer model. Oncotarget, 2017, 8, 27252-27262.	1.8	52
89	A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma. Oncotarget, 2017, 8, 37605-37618.	1.8	6
90	Chaetocin enhances dendritic cell function via the induction of heat shock protein and cancer testis antigens in myeloma cells. Oncotarget, 2017, 8, 46047-46056.	1.8	24

#	ARTICLE	IF	CITATIONS
91	Tumor necrosis and complete resection has significant impacts on survival in patients with limited-stage upper aerodigestive tract NK/T cell lymphoma. <i>Oncotarget</i> , 2017, 8, 79337-79346.	1.8	8
92	The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160). <i>Oncotarget</i> , 2017, 8, 79517-79526.	1.8	16
93	Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party. <i>Blood Research</i> , 2016, 51, 193.	1.3	6
94	Branched multipetide immunotherapy for glioblastoma using human leukocyte antigen-A*0201-restricted cytotoxic T-lymphocyte epitopes from ERBB2, BIRC5 and CD99. <i>Oncotarget</i> , 2016, 7, 50535-50547.	1.8	6
95	Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients. <i>Journal of Korean Medical Science</i> , 2016, 31, 1160.	2.5	8
96	Thalidomide-based induction regimens are as effective as bortezomib-based regimens in elderly patients with multiple myeloma with cereblon expression. <i>Annals of Hematology</i> , 2016, 95, 1645-1651.	1.8	4
97	Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML. <i>Annals of Hematology</i> , 2016, 95, 625-635.	1.8	15
98	The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea. <i>Annals of Hematology</i> , 2016, 95, 911-919.	1.8	4
99	Sarcoplasmic reticulum Ca ²⁺ ATPase 2 (SERCA2) reduces the migratory capacity of CCL21-treated monocyte-derived dendritic cells. <i>Experimental and Molecular Medicine</i> , 2016, 48, e253-e253.	7.7	15
100	Clinical impact of induction treatment modalities and optimal timing of radiotherapy for the treatment of limited-stage NK/T cell lymphoma. <i>Leukemia Research</i> , 2016, 49, 80-87.	0.8	9
101	Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen. <i>BMC Cancer</i> , 2016, 16, 613.	2.6	24
102	Na ⁺ -ve CD8 ⁺ T cell derived tumor-specific cytotoxic effectors as a potential remedy for overcoming TGF- β immunosuppression in the tumor microenvironment. <i>Scientific Reports</i> , 2016, 6, 28208.	3.3	36
103	Prognostic factors for re-mobilization using plerixafor and granulocyte colony-stimulating factor (G-CSF) in patients with malignant lymphoma or multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy: the Korean multicenter retrospective study. <i>Annals of Hematology</i> , 2016, 95, 603-611.	1.8	7
104	Clinical Features and Survival of Patients With Follicular Lymphoma in Korea. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 197-202.	0.4	4
105	Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant. <i>Annals of Hematology</i> , 2016, 95, 301-310.	1.8	26
106	DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 61-70.	2.0	43
107	Prognostic value of the inverse platelet to lymphocyte ratio (iPLR) in patients with multiple myeloma who were treated up front with a novel agent-containing regimen. <i>Annals of Hematology</i> , 2016, 95, 55-61.	1.8	9
108	Replication of New Genomic Classification System in Acute Myeloid Leukemia with Normal Karyotype. <i>Blood</i> , 2016, 128, 2876-2876.	1.4	0

#	ARTICLE	IF	CITATIONS
109	The Outcomes of Korean Patients with Primary Plasma Cell Leukemia: Analysis of Korean Multiple Myeloma Working Party (KMM160). <i>Blood</i> , 2016, 128, 4445-4445.	1.4	0
110	Adverse prognostic effect of homozygous TET2 mutation on the relapse risk of acute myeloid leukemia in patients of normal karyotype. <i>Haematologica</i> , 2015, 100, e351-e353.	3.5	31
111	Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. <i>Blood</i> , 2015, 126, 746-756.	1.4	160
112	L-Asparaginase delivered by <i>Salmonella typhimurium</i> suppresses solid tumors. <i>Molecular Therapy - Oncolytics</i> , 2015, 2, 15007.	4.4	38
113	Lenalidomide Synergistically Enhances the Effect of Dendritic Cell Vaccination in a Model of Murine Multiple Myeloma. <i>Journal of Immunotherapy</i> , 2015, 38, 330-339.	2.4	65
114	Dendritic Cell-Based Cancer Immunotherapy against Multiple Myeloma: From Bench to Clinic. <i>Chonnam Medical Journal</i> , 2015, 51, 1.	0.9	27
115	Use of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in Korea. <i>Blood Research</i> , 2015, 50, 7.	1.3	4
116	Comparison of Fc γ 3-Deficient and CD57+ Natural Killer Cells Between Cord Blood and Adult Blood in the Cytomegalovirus-Endemic Korean Population. <i>Annals of Laboratory Medicine</i> , 2015, 35, 423-428.	2.5	5
117	Predictive Efficacy of Interim Positron Emission Tomography/Computed Tomography (PET/CT) for the Treatment of Aggressive Lymphoma. <i>Chonnam Medical Journal</i> , 2015, 51, 109.	0.9	1
118	Oliguria as an early indicator of mortality risk in patients with multiple myeloma and renal impairment. <i>Blood Research</i> , 2015, 50, 167.	1.3	1
119	Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia. <i>Blood Research</i> , 2015, 50, 19.	1.3	24
120	Branched Polyethylenimine-Superparamagnetic Iron Oxide Nanoparticles (bPEI-SPIONs) Improve the Immunogenicity of Tumor Antigens and Enhance Th1 Polarization of Dendritic Cells. <i>Journal of Immunology Research</i> , 2015, 2015, 1-9.	2.2	33
121	Cellular immunotherapy as a beacon of hope for hematological malignancies. <i>Blood Research</i> , 2015, 50, 126.	1.3	7
122	The anti-canine distemper virus activities of ex vivo-expanded canine natural killer cells. <i>Veterinary Microbiology</i> , 2015, 176, 239-249.	1.9	11
123	Interleukin-21 induces proliferation and modulates receptor expression and effector function in canine natural killer cells. <i>Veterinary Immunology and Immunopathology</i> , 2015, 165, 22-33.	1.2	11
124	The t(11;14)(q13;q32) Translocation as a Poor Prognostic Parameter for Autologous Stem Cell Transplantation in Myeloma Patients With Extramedullary Plasmacytoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 227-235.	0.4	19
125	Prognostic significance of interim PET/CT based on visual, SUV-based, and MTV-based assessment in the treatment of peripheral T-cell lymphoma. <i>BMC Cancer</i> , 2015, 15, 198.	2.6	28
126	Clinical Outcomes and Prognostic Factors of Up-Front Autologous Stem Cell Transplantation in Patients with Extranodal Natural Killer/T Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1597-1604.	2.0	76

#	ARTICLE	IF	CITATIONS
127	Generation of potent dendritic cells with improved migration ability through p-cofilin and sarco/endoplasmic reticulum Ca ²⁺ transport ATPase 2 regulation. <i>Cytotherapy</i> , 2015, 17, 1421-1433.	0.7	15
128	Weekly rituximab consolidation following four cycles of R ^{sc} CHOP ^{sc} induction chemotherapy in very elderly patients with diffuse large B ^{cell} lymphoma: Consortium for improving survival of lymphoma study (<sc>CISL</sc>). <i>European Journal of Haematology</i> , 2015, 94, 504-510.	2.2	16
129	Pancreatic adenocarcinoma upregulated factor serves as adjuvant by activating dendritic cells through stimulation of TLR4. <i>Oncotarget</i> , 2015, 6, 27751-27762.	1.8	22
130	Dendritic cell vaccination with a toll-like receptor agonist derived from mycobacteria enhances anti-tumor immunity. <i>Oncotarget</i> , 2015, 6, 33781-33790.	1.8	27
131	Treatment of BK virus-associated hemorrhagic cystitis with low-dose intravenous cidofovir in patients undergoing allogeneic hematopoietic cell transplantation. <i>Korean Journal of Internal Medicine</i> , 2015, 30, 212.	1.7	27
132	Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis. <i>Cancer Research and Treatment</i> , 2015, 47, 173-181.	3.0	10
133	Clinical significance of radiotherapy in the treatment of limited stage NK/T cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8549-8549.	1.6	0
134	Discrepancy of Interim PET/CT Responses Based on Visual and Quantitative SUV-Based Assessments in the Patients with Diffuse Large B-Cell Lymphoma and Extranodal Involvements. <i>Blood</i> , 2015, 126, 1446-1446.	1.4	0
135	<i>OCT-1</i>, <i>ABCB1</i>, and <i>ABCG2</i> Expression in Imatinib-Resistant Chronic Myeloid Leukemia Treated with Dasatinib or Nilotinib. <i>Chonnam Medical Journal</i> , 2014, 50, 102.	0.9	25
136	Clinical Outcome of Bortezomib Retreatment in Patients with Relapsed or Refractory Multiple Myeloma. <i>BioMed Research International</i> , 2014, 2014, 1-7.	1.9	8
137	Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the Consortium for Improving Survival of Lymphoma. <i>Blood Research</i> , 2014, 49, 15.	1.3	16
138	Effect of levofloxacin prophylaxis for prevention of severe infections in multiple myeloma patients receiving bortezomib-containing regimens. <i>International Journal of Hematology</i> , 2014, 100, 473-477.	1.6	17
139	Polymorphisms in DNA Repair Genes and MDR1 and the Risk for Non-Hodgkin Lymphoma. <i>International Journal of Molecular Sciences</i> , 2014, 15, 6703-6716.	4.1	18
140	The Impact of Hyperglycemia on Risk of Severe Infections during Early Period of Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma. <i>BioMed Research International</i> , 2014, 2014, 1-5.	1.9	17
141	A Bacterial Flagellin in Combination With Proinflammatory Cytokines Activates Human Monocyte-derived Dendritic Cells to Generate Cytotoxic T Lymphocytes Having Increased Homing Signals to Cancer. <i>Journal of Immunotherapy</i> , 2014, 37, 16-25.	2.4	11
142	Patterns of Relapse or Progression After Bortezomib-Based Salvage Therapy in Patients With Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 389-394.	0.4	15
143	Dendritic cells loaded with myeloma cells pretreated with a combination of JSI-124 and bortezomib generate potent myeloma-specific cytotoxic T lymphocytes in vitro. <i>Experimental Hematology</i> , 2014, 42, 274-281.	0.4	25
144	Generation of Multiple Peptide Cocktail-Pulsed Dendritic Cells as a Cancer Vaccine. <i>Methods in Molecular Biology</i> , 2014, 1139, 17-26.	0.9	11

#	ARTICLE	IF	CITATIONS
145	Decreased body mass index is associated with poor prognosis in patients with multiple myeloma. <i>Annals of Hematology</i> , 2014, 93, 835-840.	1.8	15
146	Early response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: phase II study. <i>Annals of Hematology</i> , 2014, 93, 1571-1577.	1.8	3
147	Effect of exposure to interleukin-21 at various time points on human natural killer cell culture. <i>Cytotherapy</i> , 2014, 16, 1419-1430.	0.7	35
148	Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma. <i>New England Journal of Medicine</i> , 2014, 371, 906-917.	27.0	697
149	Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1195-1206.	10.7	695
150	Advanced lytic lesion is a poor mobilization factor in peripheral blood stem cell collection in patients with multiple myeloma. <i>Journal of Clinical Apheresis</i> , 2014, 29, 305-310.	1.3	6
151	Clinical Outcomes of R-CHOP Chemotherapy Alone Compared with R-CHOP Plus Radiotherapy in Patients with Localized, Non-Bulky Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2014, 124, 4421-4421.	1.4	0
152	Lymphocytopenia is associated with an increased risk of severe infections in patients with multiple myeloma treated with bortezomib-based regimens. <i>International Journal of Hematology</i> , 2013, 97, 382-387.	1.6	19
153	Efficacy of stem cell mobilization in patients with newly diagnosed multiple myeloma after a CTD (cyclophosphamide, thalidomide, and dexamethasone) regimen. <i>International Journal of Hematology</i> , 2013, 97, 92-97.	1.6	7
154	Autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide as an intensifying frontline treatment in patients with peripheral T cell lymphomas: a multicenter retrospective trial. <i>Annals of Hematology</i> , 2013, 92, 789-797.	1.8	15
155	Interim PET/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in the post-rituximab era. <i>Annals of Hematology</i> , 2013, 92, 471-479.	1.8	69
156	Clinical outcome of elderly patients with Epstein-Barr virus positive diffuse large B-cell lymphoma treated with a combination of rituximab and CHOP chemotherapy. <i>American Journal of Hematology</i> , 2013, 88, 774-779.	4.1	33
157	Poor prognostic significance of <i>Mycobacterium tuberculosis</i> infection during bortezomib-containing chemotherapy in patients with multiple myeloma. <i>Blood Research</i> , 2013, 48, 35.	1.3	12
158	Initial Phase 3 Results Of The First (Frontline Investigation Of Lenalidomide + Dexamethasone Versus) Tj ETQq0 0 0 rgBT /Overlock 10 Tf (Pts) Ineligible For Stem Cell Transplantation (SCT). <i>Blood</i> , 2013, 122, 2-2.	1.4	39
159	A Phase III Study Of Enzastaurin In Patients With High-Risk Diffuse Large B Cell Lymphoma Following Response To Primary Treatment: The Prelude Trial. <i>Blood</i> , 2013, 122, 371-371.	1.4	8
160	Serum Level Of Parathyroid Hormone Is Associated With Risk Factors and Clinical Outcomes In Multiple Myeloma. <i>Blood</i> , 2013, 122, 5365-5365.	1.4	1
161	The Prognostic Significance Of Interim PET/CT Using Visual, SUV-Based and MTV-Based Assessment In Treatment Of Peripheral T Cell Lymphoma. <i>Blood</i> , 2013, 122, 4261-4261.	1.4	0
162	Nilotinib Combined With Multi-Agent Chemotherapy For Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Final Results Of Prospective Multicenter Phase 2 Study. <i>Blood</i> , 2013, 122, 55-55.	1.4	4

#	ARTICLE	IF	CITATIONS
163	Ex vivo expansion of natural killer cells using cryopreserved irradiated feeder cells. <i>Anticancer Research</i> , 2013, 33, 2011-9.	1.1	15
164	Immunotherapy Using Dendritic Cells against Multiple Myeloma: How to Improve?. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-13.	3.3	26
165	<i>In vitro</i> induction of anterior gradient-2-specific cytotoxic T lymphocytes by dendritic cells transduced with recombinant adenoviruses as a potential therapy for colorectal cancer. <i>Experimental and Molecular Medicine</i> , 2012, 44, 60.	7.7	15
166	Pilot trial of yttrium-90 ibritumomab tiuxetan consolidation following rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone chemotherapy in patients with limited-stage, bulky diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 807-811.	1.3	11
167	Optimal culture conditions for the generation of natural killer cell-induced dendritic cells for cancer immunotherapy. <i>Cellular and Molecular Immunology</i> , 2012, 9, 45-53.	10.5	17
168	Cellular Immunotherapy Using Dendritic Cells Against Multiple Myeloma. , 2012, , .		0
169	Cellular immunotherapy using dendritic cells against multiple myeloma. <i>The Korean Journal of Hematology</i> , 2012, 47, 17.	0.7	9
170	A comparison of bortezomib, cyclophosphamide, and dexamethasone (Vel-CD) chemotherapy without and with thalidomide (Vel-CTD) for the treatment of relapsed or refractory multiple myeloma. <i>Annals of Hematology</i> , 2012, 91, 1023-1030.	1.8	12
171	Whole Exome Sequencing Analysis in AML with Normal Karyotype Not Harboring FLT3/ITD Mutation Reveals Novel Genetic Alterations.. <i>Blood</i> , 2012, 120, 2593-2593.	1.4	0
172	NPM1, IDH1/2 and DNAM1 Gene Mutations Can Improve a Prognostic Stratification of Acute Myeloid Leukemia Patients with Normal Karyotype but Not Harboring FLT3/ITD Mutation.. <i>Blood</i> , 2012, 120, 2534-2534.	1.4	0
173	Lenalidomide Synergistically Enhances the Effect of Dendritic Cell Vaccination in Mouse Multiple Myeloma Model. <i>Blood</i> , 2012, 120, 5010-5010.	1.4	1
174	Prognostic significance of interim 18F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma. <i>European Journal of Cancer</i> , 2011, 47, 1312-1318.	2.8	82
175	Induction of myeloma-specific cytotoxic T lymphocytes responses by natural killer cells stimulated-dendritic cells in patients with multiple myeloma. <i>Leukemia Research</i> , 2011, 35, 1241-1247.	0.8	12
176	Successful cross-presentation of allogeneic myeloma cells by autologous alpha-type 1-polarized dendritic cells as an effective tumor antigen in myeloma patients with matched monoclonal immunoglobulins. <i>Annals of Hematology</i> , 2011, 90, 1419-1426.	1.8	13
177	Type I and II interferons enhance dendritic cell maturation and migration capacity by regulating CD38 and CD74 that have synergistic effects with TLR agonists. <i>Cellular and Molecular Immunology</i> , 2011, 8, 341-347.	10.5	55
178	A Case of Disseminated and Fulminant Plasmacytomas That Developed during Bortezomib Treatment. <i>Case Reports in Oncology</i> , 2011, 4, 101-105.	0.7	4
179	Low-dose Acyclovir is Effective for Prevention of Herpes Zoster in Myeloma Patients Treated with Bortezomib: A Report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 353-357.	1.3	28
180	Alpha-Type 1 Polarized Dendritic Cells Loaded with Apoptotic Allogeneic Breast Cancer Cells Can Induce Potent Cytotoxic T Lymphocytes against Breast Cancer. <i>Cancer Research and Treatment</i> , 2011, 43, 56-66.	3.0	12

#	ARTICLE	IF	CITATIONS
181	The Lymphoid Chemokine CCL21 Enhances the Migration- and CTL-Inducing Functions of Dendritic Cells. <i>Blood</i> , 2011, 118, 1127-1127.	1.4	0
182	Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study. <i>Annals of Hematology</i> , 2010, 89, 475-482.	1.8	47
183	Alpha-type 1-polarized dendritic cells loaded with apoptotic allogeneic myeloma cell line induce strong CTL responses against autologous myeloma cells. <i>Annals of Hematology</i> , 2010, 89, 795-801.	1.8	25
184	Clinical significance of clonality and Epstein-Barr virus infection in adult patients with hemophagocytic lymphohistiocytosis. <i>American Journal of Hematology</i> , 2010, 85, 719-722.	4.1	51
185	Soluble syndecan-1 (CD138): is it useful as a prognostic factor in Korean patients with multiple myeloma?. <i>The Korean Journal of Hematology</i> , 2010, 45, 143.	0.7	1
186	Induction Treatment With Cyclophosphamide, Thalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: A Phase II Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 62-67.	0.4	13
187	Clinical Correlation of CD4+CD25+ Regulatory T Cells in Early Immune Reconstitution after Myeloablative Allogeneic Stem Cell Transplantation. <i>Chonnam Medical Journal</i> , 2009, 45, 154.	0.1	0
188	Polymyositis and myocarditis after donor lymphocyte infusion. <i>International Journal of Hematology</i> , 2009, 90, 113-116.	1.6	14
189	The combined evaluation of interim contrast-enhanced computerized tomography (CT) and FDG-PET/CT predicts the clinical outcomes and may impact on the therapeutic plans in patients with aggressive non-Hodgkin's lymphoma. <i>Annals of Hematology</i> , 2009, 88, 425-432.	1.8	28
190	Induction of myeloma-specific cytotoxic T lymphocytes ex vivo by CD40-activated B cells loaded with myeloma tumor antigens. <i>Annals of Hematology</i> , 2009, 88, 1113-1123.	1.8	14
191	The dysfunction and abnormal signaling pathway of dendritic cells loaded by tumor antigen can be overcome by neutralizing VEGF in multiple myeloma. <i>Leukemia Research</i> , 2009, 33, 665-670.	0.8	62
192	Prognostic Factors and Clinical Outcomes of High-Dose Chemotherapy followed by Autologous Stem Cell Transplantation in Patients with Peripheral T Cell Lymphoma, Unspecified: Complete Remission at Transplantation and the Prognostic Index of Peripheral T Cell Lymphoma Are the Major Factors Predictive of Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 118-125.	2.0	49
193	Autologous Versus Allogeneic Hematopoietic Stem Cell Transplantation (SCT) for Peripheral T-Cell Lymphomas (PTCLs): Japan and Korea Cooperative Study with 330 Patients.. <i>Blood</i> , 2009, 114, 2284-2284.	1.4	1
194	The Prognostic Impact of Fluorescent-in Situ Hybridization (FISH) and Conventional Karyotyping in Korean Multiple Myeloma Patients: A Retrospective Multicenter Study.. <i>Blood</i> , 2009, 114, 4902-4902.	1.4	1
195	Improved Survival of Patients with Multiple Myeloma and the Impact of Transplantation and Novel Agents: An Analysis of the Korean Multiple Myeloma Working Party (KMMWP).. <i>Blood</i> , 2009, 114, 4881-4881.	1.4	0
196	Phase II Trial of 90y-Ibritumomab Tiuxetan Treatment as Consolidation After 6th R-CHOP Chemotherapy in Patients with Limited-Stage, Bulky Diffuse Large B Cell Lymphoma.. <i>Blood</i> , 2009, 114, 3751-3751.	1.4	1
197	Monocyte-derived dendritic cells from HLA-matched allogeneic donors showed a greater ability to induce leukemic cell-specific T cells in comparison to leukemic cell-derived dendritic cells or monocyte-derived dendritic cells from AML patients. <i>Leukemia Research</i> , 2008, 32, 1653-1660.	0.8	13
198	Association between folate-metabolizing pathway polymorphism and non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2008, 140, 287-294.	2.5	77

#	ARTICLE	IF	CITATIONS
199	Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia. <i>Journal of Leukocyte Biology</i> , 2008, 84, 319-325.	3.3	71
200	Ability of Mature Dendritic Cells to Interact with Regulatory T Cells Is Imprinted during Maturation. <i>Cancer Research</i> , 2008, 68, 5972-5978.	0.9	161
201	Natural Killer (NK) or NK/T Cell Lineage Large Granular Lymphocytosis Associated with Dasatinib Therapy for Philadelphia Chromosome Positive Leukemia.. <i>Blood</i> , 2008, 112, 933-933.	1.4	2
202	Polymorphisms in Myeloid Cell Leukemia-1 and the Risk for Acute Myeloid Leukemia. <i>Blood</i> , 2008, 112, 3977-3977.	1.4	0
203	GST T1 and GST M1 Polymorphisms Are Associated with the Risk of Acute Myeloid Leukemia. <i>Blood</i> , 2008, 112, 3978-3978.	1.4	0
204	Induction of multiple myeloma-specific cytotoxic T lymphocyte stimulation by dendritic cell pulsing with purified and optimized myeloma cell lysates. <i>Leukemia and Lymphoma</i> , 2007, 48, 2022-2031.	1.3	43
205	Interleukin-10 gene polymorphism influences the prognosis of T-cell non-Hodgkin lymphomas. <i>British Journal of Haematology</i> , 2007, 137, 329-336.	2.5	30
206	Optimization and Limitation of Calcium Ionophore to Generate DCs from Acute Myeloid Leukemic Cells. <i>Cancer Research and Treatment</i> , 2007, 39, 175.	3.0	1
207	No Reversal of Demethylation after Azacitidine Treatment in Concordance with Poor Clinical Response.. <i>Blood</i> , 2007, 110, 4629-4629.	1.4	0
208	Down-regulation of cellular vascular endothelial growth factor levels induces differentiation of leukemic cells to functional leukemic-dendritic cells in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2006, 47, 2224-2233.	1.3	10
209	A Multicenter Retrospective Analysis of Adverse Events in Korean Patients Using Bortezomib for Multiple Myeloma. <i>International Journal of Hematology</i> , 2006, 83, 309-313.	1.6	32
210	Induction of Myeloma Cell Line-specific Cytotoxic T Lymphocytes using Monocyte-derived Dendritic Cells Pulsed with Myeloma Cell Line Lysates. <i>The Korean Journal of Hematology</i> , 2006, 41, 186.	0.7	0
211	Selective Expansion of Natural Killer Cells from Peripheral Blood Mononuclear Cells by K562 Cell Line and IL-2. <i>The Korean Journal of Hematology</i> , 2006, 41, 8.	0.7	0
212	Clinical Usefulness and Therapeutic Plan with Interim PET/CT Analysis in Malignant Lymphoma.. <i>Blood</i> , 2006, 108, 2403-2403.	1.4	0
213	Clinical Correlation of Foxp3 Regulatory Gene Expressions and NK Cells in Early Engraftment after Myeloablative Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2006, 108, 2911-2911.	1.4	0
214	The Impact of Alemtuzumab as a Component of Conditioning Regimens on Transplantation Outcomes in a Setting of CMV-Seropositive Recipient and Donor.. <i>Blood</i> , 2006, 108, 5270-5270.	1.4	0
215	Interleukin-10 (IL-10) Promoter Gene Polymorphism ($\hat{\sim}819^*C$) Associated with Poor Clinical Outcome in DLBCL Patients Treated with R (Rituximab)-CHOP Regimen as a First Line.. <i>Blood</i> , 2005, 106, 1923-1923.	1.4	0
216	A Comparison of 3 Staging Systems for the Outcome Following Autologous Stem Cell Transplantation (ASCT) in Patients with Multiple Myeloma (MM).. <i>Blood</i> , 2005, 106, 5479-5479.	1.4	0

#	ARTICLE	IF	CITATIONS
217	Predictable Prognostic Factor of CD56 Expression in Acute Myeloid Leukemia with t(8:21) Including Allogeneic Hematopoietic Stem Cell Transplantation.. Blood, 2005, 106, 3288-3288.	1.4	0
218	Comparison of the Peripheral Blood Stem Cell Mobilization and Harvest after Each Consolidation Chemotherapy in Patients with Acute Myeloid Leukemia in First Complete Remission Who Underwent Autologous Stem Cell Transplantation.. Blood, 2005, 106, 5495-5495.	1.4	1
219	Toxicity Profiles in Patients Using Bortezomib for Multiple Myeloma: Korean Multicenter Analysis.. Blood, 2005, 106, 3500-3500.	1.4	0
220	Modified Thalidomide, Cyclophosphamide and Dexamethasone (TCD) to Patients with Multiple Myeloma as Primary Therapy Prior to Peripheral Blood Stem Cell Collection.. Blood, 2005, 106, 5173-5173.	1.4	0
221	The Feasibility Study for Using FLT3/ITD as a Marker of the Minimal Residual Disease (MRD) in Patients with Acute Myeloid Leukemia (AML) by Serial Analysis in Diagnosis, Remission and Relapse.. Blood, 2005, 106, 4515-4515.	1.4	0
222	Immunotherapy using autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation. Journal of Clinical Apheresis, 2004, 19, 66-70.	1.3	68
223	The generation of leukemic dendritic cells from acute myeloid leukemia cells is potentiated by the addition of CD40L at the terminal maturation stage. Journal of Clinical Apheresis, 2004, 19, 130-136.	1.3	8
224	Generation of cytotoxic donor CD8+ T cells against relapsing leukemic cells following allogeneic transplantation by stimulation with leukemic cell- or leukemic lysate pulsed donor cell-derived dendritic cells. Leukemia Research, 2004, 28, 517-524.	0.8	23
225	Clinical Significance of FLT3 Internal Tandem Duplication in Patients with Acute Myeloid Leukemia Who Underwent Allogeneic Bone Marrow Transplantation.. Blood, 2004, 104, 4419-4419.	1.4	0
226	The Role of PGE2 in the Differentiation of Dendritic Cells: How Do Dendritic Cells Influence T-Cell Polarization and Chemokine Receptor Expression?. Stem Cells, 2002, 20, 448-459.	3.2	53
227	Hemorrhagic Fever with Renal Syndrome Presenting with Hemophagocytic Lymphohistiocytosis. Emerging Infectious Diseases, 2002, 8, 209-210.	4.3	26
228	Increased angiogenesis and Fas-ligand expression are independent processes in acute myeloid leukemia. Leukemia Research, 2001, 25, 1067-1073.	0.8	18
229	Cellular Immunotherapy Using Dendritic Cells in Multiple Myeloma: New Concept to Enhance Efficacy. , 0, , .		0